CCL11 and colon adenocarcinoma: These discoveries implied that immunotherapy drugs which are effective in treating COAD with wild-type CDH1, CCL11, NOS2, NAT2, TIMP1 and TP53, maybe insensitive to the patients with the genetic alterations about deep deletion, high amplification, arm-level deletion and gain.